Research Article

Choline Protects the Heart from Doxorubicin-Induced Cardiotoxicity through Vagal Activation and Nrf2/HO-1 Pathway

Fuding Guo, Yueyi Wang, Jun Wang, Zhihao Liu, Yanqiu Lai, Zhen Zhou, Zihan Liu, Yuyang Zhou, Xiao Xu, Zeyan Li, Meng Wang, Fu Yu, Ruijie Hu, Liping Zhou, and Hong Jiang

1Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China
2Cardiac Autonomic Nervous System Research Centre of Wuhan University, Wuhan, China
3Cardiovascular Research Institute, Wuhan University, Wuhan, China
4Hubei Key Laboratory of Cardiology, Wuhan, China

Correspondence should be addressed to Hong Jiang; hong-jiang@whu.edu.cn

Fuding Guo, Yueyi Wang, and Jun Wang contributed equally to this work.

Received 14 December 2021; Accepted 14 March 2022; Published 5 April 2022

Academic Editor: Vladimir Jakovljevic

Copyright © 2022 Fuding Guo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Choline is a precursor of the major neurotransmitter acetylcholine and has been demonstrated beneficial in diverse models of cardiovascular disease. Here, we sought to verify that choline protects the heart from DOX-induced cardiotoxicity and the underlying mechanisms. The results showed that DOX treatment decreased left ventricular ejection fraction and fractional shortening and increased serum cardiac markers and myocardial fibrosis, which were alleviated by cotreatment with choline. DOX-induced cardiotoxicity was accompanied by increases in oxidative stress, inflammation, and apoptosis, which were rectified by choline cotreatment. Levels of nuclear factor erythroid 2-related factor 2 (Nrf2) and heme-oxygenase-1 (HO-1), which are antioxidant markers, were lowered by DOX and upregulated by choline. Moreover, DOX significantly decreased serum acetylcholine levels and the high-frequency component of heart rate variability and increased serum norepinephrine levels and the low-frequency component; these effects were rescued by choline administration. Interestingly, the protective effects of choline could be partially reversed by administration of the muscarinic receptor antagonist atropine. This suggests that choline might be a promising adjunct therapeutic agent to alleviate DOX-induced cardiotoxicity.

1. Introduction

Doxorubicin (DOX) is the most commonly used anthracycline drug against various cancers (breast cancer, Hodgkin’s disease, lymphoblastic leukemia, etc.) [1, 2]. A growing stream of clinical evidences indicated that DOX has severe toxic effects on cardiac tissues, which limited the use and the therapeutic dosages of DOX [3–5]. DOX-induced cardiotoxicity has been postulated to have multiple mechanisms involving mitochondrial dysfunction, cardiomyocyte apoptosis [6–9], and increased oxidative stress and inflammation with the excessive production of reactive oxygen species (ROS) [10]. However, both ROS scavenging agents and anti-inflammatory agents, with the exception of dextrazoxane, failed to limit DOX-induced cardiotoxicity. Basic and clinical studies indicate that exposure to DOX is associated with autonomic nervous system dysfunction and cardiac dysfunction, particularly heart failure [11, 12], whereas the nonselective β-adrenoceptor antagonist carvedilol ameliorates DOX-induced side effects and significantly improves left ventricular function [12]. A shift in cardiac autonomic balance toward enhanced sympathetic tone occurs early during the administration of DOX-based chemotherapy, and the activated sympathetic tone results in abnormal neurohormone secretion, which is a simultaneous trigger for left ventricular dysfunction [13, 14]. Meanwhile, DOX treatment caused cardiac
Control

Saline

3 doses of DOX (5mg/kg, i.p.) within a period of 2 weeks

DOX

Choline

Choline (7 mg/kg/d, i.p.) within a period of 5 weeks

DOX + Choline

3 doses of DOX (5mg/kg, i.p.) within a period of 2 weeks

Choline (7 mg/kg/d, i.p.) within a period of 5 weeks

DOX + Choline + Atro

3 doses of DOX (5mg/kg, i.p.) within a period of 2 weeks

Choline (7 mg/kg/d, i.p.) within a period of 5 weeks

Atropine (0.6 m/kg/d, i.p.) within a period of 5 weeks

Day 0 Day 7 Day 14 Day 35

(a)

(b)

(c)

(d)

Figure 1: Continued.

Oxidative Medicine and Cellular Longevity
Autonomic imbalance accompanied by elevated oxidative stress and histological changes in the heart tissue [15]. Although numerous studies have tried to understand the pathophysiology of DOX-induced cardiotoxicity, no effective treatment is available. However, increased vagal activity may represent a promising treatment strategy against DOX-induced cardiotoxicity, and it is necessary to further find effective pharmaceutical therapies for the activation of vagal tone in DOX-induced cardiotoxicity.

Choline, the precursor of the primary vagal neurotransmitter acetylcholine (Ach), confers protective benefits against numerous cardiovascular disorders, such as hypertension, myocardial infarction, ischemia/reperfusion injury, arrhythmia, and myocardial hypertrophy [16–20]. Choline exerts a remarkable cardioprotective effect by inhibiting ROS [18], preventing calcium overload [18], regulating mitochondrial dysfunction [20], and alleviating the inflammatory response [16], which are associated with improved vagal activity.

**Figure 1**: Schematic protocol for rat treatments and echocardiography. (a) Study procedure of each group. (b) The survival curves were shown \((n = 10-15\) per group). (c) Representative echocardiography images of rats from various groups. (d–g) LVEF%, FS%, LVIDs, and LVIDd were assessed by echocardiography. \(n = 6\). \(* P < 0.05, ** P < 0.001, \text{and} *** P < 0.0001\). LVEF%: left ventricular ejection fraction; FS: fractional shortening; LVIDs: left ventricular internal dimension in systole; LVIDd: left ventricular internal dimension in diastole.
Figure 2: Continued.
Choline treatment can rebalance vagal and sympathetic activity, as evidenced by improved parameters of heart rate variability (HRV), increased serum Ach levels, and enhanced baroreflex sensitivity [16, 20]. However, it remains unclear whether choline can protect the heart against DOX-induced cardiotoxicity. In this study, we investigated the cardioprotective effects of choline in DOX-induced cardiotoxicity and explored the potential mechanisms, which offers a novel therapeutic tactic for DOX-induced cardiotoxicity.

2. Methods

2.1. Animal Preparation and Experimental Protocols. All experimental operations were in accordance with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health Publication No. 85-23, revised 1996) and were approved by the Animal Welfare & Ethics Committee of Renmin Hospital of Wuhan University (approval number: WDRM20170620). Adult male Sprague–Dawley (SD) rats weighing 180–200 g were acquired from Vital River Co. Ltd. (Beijing, China) and were fed in a 12/12 h light/dark cycle with free access to food and water. The rats were treated with doxorubicin (HY-15142, MCE) (5 mg/kg) three times on days 0, 7, and 14 via intraperitoneal (i.p.) injection. The schematic protocol for rat treatments is shown in Figure 1(a). The animals were acclimatized for 1 week and randomly divided into five groups: (1) control group—rats received only sterile saline; (2) DOX group—rats were injected with DOX (5 mg/kg) on days 0, 7, and 14 based on previous reports [14, 21]; (3) choline group—rats were injected with choline (HY-26978, MCE) (7 mg/kg/d, i.p.); (4) DOX+choline group—rats were injected with the abovementioned DOX and choline doses every day; and (5) DOX+choline+atropine (Atro)—atropine (HY-B1205) (0.6 mg/kg/d, i.p.) was injected into rats prior to the administration of choline and DOX and then concurrently with them each day. The dosages of choline and atropine were selected based on previous reports [20].

2.2. Echocardiography. Rats were anesthetized with isoflurane (induction 4% and thereafter 1.5%) after administration for 5 weeks. Transthoracic echocardiography was used to assess cardiac function in superficial anesthesia rats using a high-resolution imaging system (GE Vivid E95, USA, 12-MHz transducer) as previously reported [14]. The testing and analysis were conducted blinded to the experimental grouping and treatment. The left ventricle ejection fraction (LVEF%), LV fractional shortening (FS%), and LV internal diameter in systole and diastole (LVIDs and LVIDd, respectively) were assessed.

2.3. Measurement of Heart Rate Variability. All surface electrocardiograms were recorded to measure HRV by using a Power Lab data acquisition system (AD Instruments, New South Wales, Australia) with 1.5% isoflurane inhalation. Low-frequency (LF) power in the frequency range 0.20–0.75 Hz, which is related to the interaction of cardiac sympathetic and vagal influences, and high-frequency (HF) power in the 0.75–2.5 Hz frequency band, which is exclusively under vagal regulation, were used to test power spectrum analysis and were described in previous studies [22]. HRV’s normalized LF power has been suggested to reflect sympathetic cardiac modulation, particularly when the cardiac sympathetic drive is active [23]. The LF/HF ratio was determined and used as a measure of sympathovagal balance.

2.4. Serum Biochemistry and ELISA Analysis. Blood was obtained from the abdominal aorta of each rat at the end of the experiment. Approximately 4 ml of blood was subjected to a standard separation procedure by centrifugation.
Figure 3: Continued.
Figure 3: Continued.
at 3000 rpm for 15 min at 4°C, and then, samples were isolated and stored at −80°C. Serum levels of creatine kinase (CK), creatine kinase-MB (CK-MB), and lactate dehydrogenase (LDH) were measured with an autonomic biochemical analyzer. Malondialdehyde (MDA), superoxide dismutase (SOD), glutathione peroxidase (GSH-PX) activity, and Ach in serum were analyzed using commercial kits following the manufacturer’s protocols (Nanjing Jiancheng Bioengineering Institute, Nanjing, China).

Serum catalase (CAT), hydrogen peroxide (H₂O₂), glutathione (GSH), and norepinephrine (NE) were analyzed using a commercial ELISA kit (Wuhan Msk Bio Bioengineering Institute, Wuhan, China) according to the manufacturer’s instructions.

2.5. Evaluation of Inflammatory Response. Small pieces of cardiac tissue were homogenized and centrifuged (1000 g × 10 min, 4°C), and the supernatant was collected carefully for analysis. The tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β) levels were analyzed using a commercial ELISA kit according to the manufacturer’s instructions.

2.6. Evaluation of Oxidative Stress. SOD and MDA in cardiac tissue were measured using assay kits (Nanjing Jiancheng Bioengineering Institute, Nanjing, China) according to the manufacturer’s protocol to evaluate the levels of oxidative stress.

2.7. Histological Analysis. At the end of the experiment, heart tissues from the 5 groups were isolated, washed, fixed in 4% formalin, and embedded in paraffin. Then, the tissues were sliced into 4 μm thick sections and stained with hematoxylin and eosin (H&E) and Masson’s trichrome. The positively stained (blue) fibrotic area was analyzed using Image-Pro Plus v.6.0. For each section, the average percentage of fibrosis to total area was determined using six random images.

2.8. TUNEL Staining Analysis. Cardiac apoptosis in myocardial tissue was determined by a TUNEL kit (Roche, Germany) according to the manufacturer’s instructions. Apoptosis was assessed using fluorescence microscopy, and relative quantification was analyzed using Image-Pro Plus v.6.0. The ratio of TUNEL-positive nuclei to DAPI-stained nuclei in six random images per slide was used to assess apoptosis.

2.9. Immunofluorescence Staining. ROS production was assessed by ROS staining solution (D7008, SIGMA) in fresh-frozen myocardial sections of the left ventricle. Briefly, the frozen sections were restored to room temperature and agitated in an autofluorescence quenching solution on an orbital shaker. Next, ROS staining solution was added, and the slices were incubated at 37°C for 30 min in the dark. The nuclei were counterstained with DAPI. Finally, the slices were mounted on slides and imaged under a microscope. The fluorescence intensity in the myocardial sections was quantified with Image-Pro Plus v.6.0 as a measure of ROS.

2.10. Western Blotting. The heart’s LV was snap frozen and lysed with RIPA solution. SDS-PAGE was used to separate the isolated protein (40 μg), which was then transferred onto
Figure 4: Continued.
Figure 4: Effect of choline treatment on proinflammatory factors in cardiac tissue. (a–c) IL-6, IL-1β, and TNF-α levels were measured in cardiac tissue; n = 6. (d) Immunofluorescence of IL-6 in cardiac tissue; bar = 50 μm. (e) Quantitative analysis of the fold change in IL-6; n = 4. **P < 0.01, ***P < 0.001, and ****P < 0.0001. IL-6: interleukin-6; IL-1β: interleukin-1β; TNF-α: tumor necrosis factor alpha.
Figure 5: Continued.
polyvinylidene fluoride membranes and incubated at room temperature for 1 h. Then, the membranes were incubated with primary antibody overnight at 4 °C. The following primary antibodies were used: cleaved caspase 3 (c-caspase 3, 1:500, Cell Signaling Technology, Boston, USA), Bax (1:500, Abcam, Cambridge, UK), Bcl-2 (1:500, Abcam, Cambridge, UK), Nrf2 (1:500, Gene Technology, Shanghai, China), and HO-1 (1:200, Santa Cruz, CA, USA). After washing 4 times in TBST for 5 min, the membranes were incubated with goat anti-rabbit antibody HRP-conjugated secondary antibody (1:5000 to 1:10000; Cell Signaling Technology, Boston, USA) at room temperature for 1 h in the dark. After washing with TBST, the band intensities were analyzed by the Odyssey Imaging System (LICOR Biosciences, Lincoln, USA).

2.11. Statistical Analysis. All data are presented as the mean ± standard deviation (SD). Between-group differences

---

**Figure 5:** Effect of choline treatment on apoptosis in cardiac tissue. (a) TUNEL staining; bar = 50 μm. (b) Quantitative analysis of the positive apoptotic cells (%); n = 4. (c) Western blotting bands for Bcl-2, c-caspase 3 and Bax. (d–g) Quantitative results of Bcl-2, c-caspase 3, Bax, and Bcl-2/Bax; n = 4. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
CONTROL (ctrl)  DOX  DOX + choline (DOX + cho)  DOX + choline + atropine (DOX + cho + atro)  DOX + choline + atropine (DOX + cho + atro)  DOX + choline + atropine (DOX + cho + atro)  DOX + choline + atropine (DOX + cho + atro)

DOX  DOX + choline (DOX + cho)  DOX + choline + atropine (DOX + cho + atro)  DOX + choline + atropine (DOX + cho + atro)  DOX + choline + atropine (DOX + cho + atro)  DOX + choline + atropine (DOX + cho + atro)

Choline (cho)  DOX  DOX + choline (DOX + cho)  DOX + choline + atropine (DOX + cho + atro)  DOX + choline + atropine (DOX + cho + atro)  DOX + choline + atropine (DOX + cho + atro)  DOX + choline + atropine (DOX + cho + atro)

**Figure 6: Continued.**
were assessed by Student’s t-test or one-way analysis of variance (ANOVA) as appropriate, followed by Tukey’s multiple comparisons or Bonferroni post hoc test. Kaplan-Meier survival curves were constructed and compared with the log-rank test. All statistical analyses were performed using GraphPad Prism 9 software. \( P \) values < 0.05 were considered statistically significant.

3. Results

3.1. Choline Prevented DOX-Induced Left Ventricular Dysfunction. We recorded mortality rate in rats after DOX treatment. The results showed that the survival rate was higher in the DOX+choline group than in the DOX group (Figure 1(b)). Echocardiography was performed to evaluate the effects of choline on cardiac dysfunction under DOX administration. Compared to the control group, DOX-treated rats showed significant increases in LVIDd and LVIDs, along with decreases in LVEF% and FS% (Figures 1(c)–1(g)). In contrast, the DOX+choline group showed a substantial decrease in LVIDd and LVIDs, as well as a rise in LVEF% and FS%. It is noteworthy that rats administered choline alone did not show substantial differences compared to the control.

3.2. Choline Prevented DOX-Induced Cardiac Injury and Remodeling. Histological examination showed that edema of cardiomyocytes, disordered arrangement, and inflammatory infiltrate were increased in DOX-treated rats but significantly ameliorated in the DOX+choline group (Figure 2(a)). CK, CK-MB, and LDH are the primary markers that reflect the extent of cardiac injury. Our results showed that CK, CK-MB, and LDH levels in serum were higher in the DOX group than in the control group and were attenuated by choline treatment (Figures 2(b)–2(d)). No significant difference in CK, CK-MB, or LDH levels was found between the control and choline groups. Masson’s trichrome staining showed a substantial increase in interstitial fibrosis in DOX group hearts, which was attenuated by choline coadministration (Figures 2(e) and 2(f)). These results indicate that choline treatment inhibited cardiac fibrosis and improved cardiac function from DOX-induced cardiotoxicity.

3.3. Choline Attenuated DOX-Induced Oxidative Stress. Cardiac antioxidant markers were determined by measuring SOD, GSH-Px, MDA, \( \text{H}_2\text{O}_2 \), CAT, and GSH content. As shown in Figures 3(a)–3(f), compared to the control group, the DOX group showed significantly decreased levels of SOD, GSH-Px, CAT, and GSH but with increased content of MDA and \( \text{H}_2\text{O}_2 \). In contrast, rats receiving DOX+choline showed significantly increased SOD, GSH-Px, CAT, and GSH levels and decreased MDA and \( \text{H}_2\text{O}_2 \) levels. We further explored the underlying mechanism of DOX-induced oxidative stress. The DOX group showed significantly lower expression levels of Nrf2 and HO-1 than the control group, while cotreatment with choline prevented this decrease.
Figure 7: Continued.
MDA (nmol/mgprot)

(c)

Control (ctrl)  DOX  Choline  DOX + choline  DOX + choline + atro

(d)

Figure 7: Continued.
Figure 7: Continued.
These results indicate that choline treatment could protect rats from DOX-induced oxidative stress damage by enhancing the antioxidant capability.

### 3.4. Choline Alleviated DOX-Induced Proinflammatory Markers and Apoptosis

A significant increase in the expression of the inflammatory markers IL-1β, IL-6, and TNF-α in myocardial tissue was found in the DOX group compared to the control. Treatment with choline alleviated this increase compared to the DOX group (Figures 4(a)–4(c)). Additionally, compared with the control, DOX significantly increased the expression of the proinflammatory marker IL-6 in heart tissues, and this effect was attenuated by administration of choline (Figures 4(d)–4(f)). TUNEL staining was used to further assess apoptosis in myocardial tissue, which showed higher myocardial apoptosis in the DOX group than in the control and was alleviated by choline administration (Figures 5(a) and 5(b)). Apoptosis-related proteins were further investigated via Western blot analysis. The protein levels of Bax and c-caspase 3 in cardiac tissue were increased, and Bcl-2 expression was decreased in the DOX group compared to controls (Figures 5(c)–5(g)). These results showed that choline treatment alleviated myocardial inflammation and apoptosis from DOX-induced cardiotoxicity.

### 3.5. Choline Increased the Parasympathetic Tone and Reduced DOX-Induced Sympathetic Overstimulation

To further observe changes in parasympathetic and sympathetic tones with choline treatment, we used HRV. For the frequency domain, DOX significantly decreased the HF and increased the LF and the ratio of LF/HF (Figures 6(a)–6(c)), which were reversed in the DOX+choline group. There was no significant difference in the HRV frequency domain parameters between the DOX and DOX+choline+Atro groups. The Ach level in serum was decreased, and the NE level was increased by DOX administration (Figures 6(d) and 6(e)), which were attenuated by choline treatment. Atropine, a muscarinic acetylcholine receptor antagonist, eliminated the effects of choline on HRV, Ach, and NE in DOX-induced changes, suggesting that choline can activate the vagal nerve. These results indicate that DOX-treated rats exhibited high sympathetic tone and low vagal tone, while choline treatment rebalanced autonomic activity, which was prevented by atropine.
3.6. Activation of the Vagus Nerve Mediated the Protective Effects of Choline against DOX-Induced Cardiotoxicity. To further understand how the vagus nerve plays a part in choline’s protective action against DOX-induced cardiotoxicity, rats were given atropine to block the Ach-activated component. We then determined the expression of the indicators for both oxidative stress and inflammation in cardiac tissue. As shown in Figures 7(a)–7(c), an increase in SOD activity and a decrease in MDA levels were observed in the DOX+choline group, while atropine significantly alleviated these changes. We also evaluated the ROS level in the myocardial tissue using immunofluorescence staining (Figure 7(d)). The increased generation of ROS was also decreased in DOX+choline hearts compared to the DOX group but was reversed when rats were treated with atropine (Figure 7(e)). We then assayed the expression of pro-inflammatory factors. DOX+choline hearts showed markedly lower levels of IL-6 and IL-1β than the DOX group, while cotreatment with atropine prevented this decrease (Figures 7(f) and 7(g)). There was no significant difference in the tested markers between the DOX and DOX+choline+Atro groups. These results indicated that choline alleviated DOX-induced cardiotoxicity through the activation of the vagus nerve.

4. Discussion

4.1. Major Findings. In the present study, we found that the combined use of choline from the early stage protected rats from DOX-induced cardiotoxicity, with improved cardiac function, inhibited autonomic imbalance and sympathetic predominance, and reduced myocardial apoptosis. Moreover, DOX-induced autonomic imbalance and sympathetic predominance were significantly reversed by choline. The protective effect of choline may be associated with the enhancement of vagal activity and the activation of the Nrf2/HO-1 signaling pathway in DOX-treated rats. Choline might be a promising adjunct therapeutic modality for the alleviation of DOX-induced cardiotoxicity (Supplemental Graphical Abstract available here).

4.2. Autonomic Imbalance Participates in DOX-Induced Cardiotoxicity. DOX, as a chemotherapeutic agent, is widely used for the chemotherapy of various cancers, including hematological malignancies, lymphoma, and many other types of solid tumors [2, 24]. It is known that DOX-induced cardiotoxicity is dose-dependent, cumulative, and progressive, which will cause irreversible damage to cardiomyocytes [24, 25]. Therefore, it is necessary to thoroughly understand the mechanism of cardiotoxicity and provide early cardioprotective interventions for patients before and during the DOX administration. Extensive basic research has revealed that oxidative stress, mitochondrial ROS production, metabolism dysregulation, iron metabolism, inflammation, calcium homeostasis dysregulation, autophagy, autonomic imbalance, and immunometabolism are possible underlying mechanisms of DOX-induced cardiotoxicity [10, 26, 27]. At present, dexrazoxane is the only agent licensed by the US Food and Drug Administration to reduce the cardiotoxicity induced by DOX [28]. Therefore, research on novel cardioprotective drugs or interventions has become an urgent priority in DOX-associated cardiotoxicity.

Previous studies have demonstrated that autonomic imbalance, such as sympathetic hyperactivity and parasympathetic hypoactivity, is associated with DOX-induced cardiotoxicity [11]. DOX has been shown to reduce rMSSD and HF power and increase LF power and the LF/HF ratio, which indicates a shift in the autonomic balance toward sympathetic predominance [11]. Similarly, clinical evidence found a significant correlation of LVEF% decreased with the LF/HF ratio and plasma norepinephrine levels [29]. The changes in DOX-induced HRV match the characteristics of the initial pathophysiological changes that occur in congestive heart failure, with a significant decrease in vagal tone and a significant increase in sympathetic tone [30, 31]. Moreover, the autonomic imbalance likely aggravated DOX-induced oxidative stress, the inflammatory response, and myocardial apoptosis and further exacerbated cardiac injury [14]. Previous studies have shown that vagus nerve stimulation suppresses myocardial apoptosis, oxidative stress, and inflammation via regulation of autonomic nerve balance [32, 33]. Our recent work also indicates that non-invasive transcutaneous vagal nerve stimulation is cardioprotective against DOX-induced autonomic imbalance and cardiac sympathetic nerve remodeling [14]. The present study is consistent with previous studies showing that DOX treatment significantly increased sympathetic activity and impaired vagal activity, as evidenced by the enhanced LF and LF/HF ratio associated with increased serum NE and decreased Ach levels.

4.3. Choline Ameliorates DOX-Induced Cardiotoxicity by Activating the Vagus Nerve to Correct the Autonomic Imbalance. Choline is crucial for its biological function and molecular function as a precursor of the neurotransmitter Ach. It showed a cardioprotective effect via inhibition of ROS activity and oxidative stress, restoration of intracellular calcium concentration, reduction of the levels of inflammatory factors, and enhancement of vagal activity [19, 20, 34, 35]. The latest research has shown that neuronal cholinergic pathways are conducive to the impact of choline on ameliorating cardiac hypertrophy [20]. Choline could improve HF and baroreflex sensitivity, increase serum Ach levels, and augment ΔHR in response to methylatropine administration in a rat heart cardiac hypertrophy model [16, 20].

A link between reduced vagal tone and the development of cardiovascular disease has been identified in many studies, and basic and clinical studies have revealed that boosting vagal activity could protect the heart [36–38]. The inhibition of vagus nerve activity has been reported in the heart tissue challenged with DOX therapy, which could contribute to cardiac dysfunction or damage [11]. Consequently, we hypothesized that choline could exert a protective effect in DOX-induced cardiotoxicity. In the present study, we found that choline treatment improved left ventricular dysfunction and attenuated cardiac injury, myocardial fibrosis, and apoptosis. Choline ameliorating DOX-induced cardiotoxicity is
closely related to vagus nerve activation and sympathetic nerve inhibition, as evidenced by the enhancement of HF and serum Ach levels and the decrease in LF, the LF/HF ratio, and serum NE levels, suggesting autonomic rebalance. These data suggest that cholinergic nervous activation is involved in the cardioprotective effect of choline.

4.4. Choline Protects against DOX-Induced Cardiotoxicity by Activating the Vagus Nerve to Enhance Nrf2/HO-1 Signaling. Some studies have demonstrated that the Nrf2/HO-1 signaling pathway plays a central role in regulating antioxidants in cardioprotection against oxidative stress and in DOX-induced cardiotoxicity [6, 39]. Nrf2 is an important antioxidant transcription factor that regulates multiple antioxidant defense genes (e.g., HO-1, SOD, GSH, CTA, GPX, and CAT) [40]. Under oxidative stress, the Nrf2 signaling pathway is activated and leads to downstream transcription of antioxidant factors, particularly HO-1 [41]. HO-1 is a novel enzyme with powerful antioxidant and anti-inflammatory effects [42, 43]. The Nrf2/HO-1 signaling pathway can regulate oxidative stress, inflammation, and mitochondrial apoptosis [44–46]. Our previous study also suggested that one of the cardioprotective mechanisms triggered by vagus nerve stimulation is mediated by the Nrf2/HO-1 pathway [47]. In this study, the DOX-treated rats showed significantly decreased Nrf2 and HO-1 expression. In contrast, the rats cotreated with choline showed significantly higher Nrf2 and HO-1 expression. These results suggested that choline led to an increase in the expression of Nrf2 and its subsequent translocation to the nucleus, which significantly activated Nrf2/HO-1 signaling.

The Nrf2/HO-1 signaling pathway plays a key role in scavenging ROS and alleviating oxidative stress [48]. Previous studies have indicated that reducing the production of ROS is beneficial to ameliorate cardiomyopathy associated with DOX [49]. Consistent with these results, our study found that ROS production was increased under DOX administration and decreased by choline. Moreover, our results showed that DOX treatment decreased the expression of SOD, GSH-PX, GSH, and CTA compared to the control treatment. Therefore, choline treatment results in Nrf2/HO-1 activation and enhances the expression of SOD, GSH-PX, GSH, and CTA, which suggests that choline may alleviate DOX-induced cardiotoxicity through Nrf2/HO-1 redox signaling pathway activation.

Excessive oxidative stress could result in inflammatory reactions, which are also found in DOX treatment. Earlier studies suggested that DOX causes inflammatory reactions in the vasculature and myocardium and elevates the concentrations of proinflammatory cytokines (e.g., TNF-α, IL-1β, and IL-2) [50]. A critical target for anti-inflammatory action is the Nrf2/HO-1 signaling pathway [51]. In this study, DOX exposure provoked a host of proinflammatory factors, such as TNF-α, IL-1β, and IL-6; however, the inflammatory reaction was blunted by choline treatments. Notably, the effects of choline in mitigating inflammation and oxidative stress were blocked by atropine, as evidenced by the increased expression of IL-6, IL-1β, ROS, and MDA and decreased SOD activity in the heart tissue. This indicates that choline-mediated activation of the cholinergic system may represent a viable pharmacological intervention capable of inhibiting cardiac oxidative stress and inflammation by activating vagal activity and enhancing the Nrf2/HO-1 pathway.

DOX is capable of evocation the upregulation of the pro-apoptotic protein Bax, increasing apoptosis [52]. Interestingly, the transcription factor Nrf2 has been shown to upregulate the expression of antiapoptotic proteins [53]. Overexpression of Nrf2 can upregulate the expression of Bcl-2 and downregulate the expression of Bax, P53, and caspase 3 [54]. In the present study, we found that DOX treatment increased myocardial apoptosis, and this effect was alleviated by the administration of choline. Thus, we speculate that activation of the Nrf2/HO-1 signaling pathway may also reduce apoptosis against DOX-induced cardiotoxicity.

4.5. Study Limitations. The current research demonstrated the protective effect of choline against cardiotoxicity induced by a single antitumor drug, and further studies need to explore the effect of choline on cardiotoxicity caused by combination chemotherapy. Additionally, in our study, we used cancer-free rats. Further studies involving cancer models will be needed to better elucidate the complex interactions between choline, chemotherapeutic agents, the heart, and tumors and to eventually characterize the antitumor potential of choline. Furthermore, it is also interesting to investigate if choline could produce cardioprotective effects in other chemotherapeutic drug models, such as Daunorubicin, which also belongs to the anthracycline group.

5. Conclusions

The present study demonstrates for the first time that choline is able to blunt DOX-induced cardiotoxicity by inhibiting oxidative stress, inflammatory responses, and apoptosis in vivo via mechanisms that involve activation of the vagal nerve and elevation of the Nrf2/HO-1 signaling pathway.

Data Availability

The datasets used and/or analyzed during this study are available from the corresponding author on reasonable request. Requests to access these datasets should be directed to Hong Jiang (hong-jiang@whu.edu.cn).

Conflicts of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Authors’ Contributions

Fuding Guo, Yueyi Wang, and Jun Wang contributed equally to this work and are co-first authors.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (81871486, 81970287, 81530011, 81573055).
81770364, and 82100530), the Natural Science Foundation of Hubei Province (2020CFB131), and the Educational Commission of Hubei Province (B2019004).

Supplementary Materials

Supplemental Material includes a graphical abstract (Supplementary Materials)

References

[1] E. Christidi and L. R. Brunham, “Regulated cell death pathways in doxorubicin-induced cardiotoxicity,” Cell Death & Disease, vol. 12, p. 339, 2021.

[2] B. Kalyanaraman, “Teaching the basics of the mechanism of doxorubicin-induced cardiotoxicity: have we been barking up the wrong tree?,” Redox Biology, vol. 29, p. 101394, 2020.

[3] G. Curigliano, D. Cardinale, S. Dent et al., “Cardiotoxicity of anticancer treatments: epidemiology, detection, and management,” CA: a Cancer Journal for Clinicians, vol. 66, no. 4, pp. 309–325, 2016.

[4] D. Cardinale, A. Colombo, G. Bacchiani et al., “Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy,” Circulation, vol. 131, no. 22, pp. 1981–1988, 2015.

[5] S. H. Armenian, G. T. Armstrong, G. Aune et al., “Cardiovascular disease in survivors of childhood cancer: insights into epidemiology, pathophysiology, and prevention,” Journal of Clinical Oncology, vol. 36, no. 21, pp. 2135–2144, 2018.

[6] L. Zhao, Y. Qi, L. Xu et al., “MicroRNA-140-5p aggravates doxorubicin-induced cardiotoxicity by promoting myocardial oxidative stress via targeting Nrf2 and Sirt2,” Redox Biology, vol. 15, pp. 284–296, 2018.

[7] L. Li, J. Li, Q. Wang et al., “Shenmai injection protects against doxorubicin-induced cardiotoxicity via maintaining mitochondrial homeostasis,” Frontiers in Pharmacology, vol. 11, p. 815, 2020.

[8] X. Wang, Q. Wang, W. Li et al., “TFEB-NF-κB inflammatory signaling axis: a novel therapeutic pathway of dihydrotestosterone in doxorubicin-induced cardiotoxicity,” Journal of Experimental & Clinical Cancer Research, vol. 39, no. 1, p. 93, 2020.

[9] T. Tadokoro, M. Ikeda, T. Ide et al., “Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity,” JCI Insight, vol. 5, no. 9, 2020.

[10] C. Rosca, T. Pasqua, M. C. Cerra, and T. Angelone, “Cardiac damage in anthracyclines therapy: focus on oxidative stress and inflammation,” Antioxidants & Redox Signaling, vol. 32, no. 15, pp. 1081–1097, 2020.

[11] A. E. El-Naggar, S. M. El-Gowilly, and F. M. Sharabi, “Possible ameliorative effect of ivabradine on the autonomic and left ventricular dysfunction induced by doxorubicin in male rats,” Journal of Cardiovascular Pharmacology, vol. 72, no. 1, pp. 22–31, 2018.

[12] N. Kalay, E. Basar, I. Ozdogru et al., “Protective effects of carvedilol against anthracycline-induced cardiomyopathy,” Journal of the American College of Cardiology, vol. 48, no. 11, pp. 2258–2262, 2006.

[13] S. L. Guimaraes, S. C. Brandao, L. R. Andrade, R. J. C. Maia, and B. Markman Filho, “Cardiac sympathetic hyperactivity after chemotherapy: early sign of cardiotoxicity?,” Arquivos Brasileiros de Cardiologia, vol. 105, no. 3, pp. 228–234, 2015.

[14] Y. Lai, X. Zhou, F. Guo et al., "Non-invasive transcutaneous vagal nerve stimulation improves myocardial performance in doxorubicin-induced cardiotoxicity," Cardiovascular Research, 2021.

[15] R. Injac, M. Perse, M. Cerne et al., "Protective effects of fullerol C60(OH)24 against doxorubicin-induced cardiotoxicity and hepatotoxicity in rats with colorectal cancer," Biomaterials, vol. 30, no. 6, pp. 1184–1196, 2009.

[16] L. Liu, Y. Lu, X. Bi et al., “Choline ameliorates cardiovascular damage by improving vagal activity and inhibiting the inflammatory response in spontaneously hypertensive rats,” Scientific Reports, vol. 7, no. 1, p. 42553, 2017.

[17] B. Yang, H. Lin, C. Xu et al., “Choline produces cytoprotective effects against ischemic myocardial injuries: evidence for the role of cardiac m3 subtype muscarinic acetylcholine receptors,” Cellular Physiology and Biochemistry, vol. 16, no. 4-6, pp. 163–174, 2005.

[18] X. Z. Lu, X. Y. Bi, X. He et al., ”Activation of M3 cholinoreceptors attenuates vascular injury after ischaemia/reperfusion by inhibiting the Ca2+/calmodulin-dependent protein kinase II pathway,” British Journal of Pharmacology, vol. 172, no. 23, pp. 5619–5633, 2015.

[19] Y. Liu, H. L. Sun, D. L. Li et al., “Choline produces antiarrhythmic actions in animal models by cardiac M3 receptors: improvement of intracellular Ca2+ handling as a common mechanism,” Canadian Journal of Physiology and Pharmacology, vol. 86, no. 12, pp. 860–865, 2008.

[20] M. Xu, R. Q. Xue, Y. Lu et al., “Choline ameliorates cardiac hypertrophy by regulating metabolic remodelling and UPRmt through SIRT3-AMPK pathway,” Cardiovascular Research, vol. 115, no. 3, pp. 530–545, 2019.

[21] K. Suzuki, B. Murutza, N. Suzuki, R. T. Smolenski, and M. H. Yacoub, “Intracoronary infusion of skeletal myoblasts improves cardiac function in doxorubicin-induced heart failure,” Circulation, vol. 104, 12 Supplement 1, pp. I123–I127, 2001.

[22] B. Zhu, A. Hedman, S. Feng, H. Li, and W. Osika, “Designing, prototyping and evaluating digital mindfulness applications: a case study of mindful breathing for stress reduction,” Journal of Medical Internet Research, vol. 19, no. 6, p. e197, 2017.

[23] N. Chattipakorn, T. Incharoen, N. Kanlop, and S. Chattipakorn, “Heart rate variability in myocardial infarction and heart failure,” International Journal of Cardiology, vol. 120, no. 3, pp. 289–296, 2007.

[24] S. Y. van der Zanden, X. Qiao, and J. Neefjes, “New insights into the activities and toxicities of the old anticancer drug doxorubicin,” The FEBS Journal, vol. 288, no. 21, pp. 6095–6111, 2021.

[25] U. P. Mohan, T. P. P.B., S. T. A. Iqbal, and S. Arunachalam, “Mechanisms of doxorubicin-mediated reproductive toxicity - a review,” Reproductive Toxicology, vol. 102, pp. 80–89, 2021.

[26] K. B. Wallace, V. A. Sardao, and P. J. Oliveira, “Mitochondrial determinants of doxorubicin-induced cardiomyopathy,” Circulation Research, vol. 126, no. 7, pp. 926–941, 2020.

[27] J. Zhang, M. Wang, W. Ding et al., “Resolvins E1 protects against doxorubicin-induced cardiotoxicity by inhibiting oxidative stress, autophagy and apoptosis by targeting AKT/mTOR signaling,” Biochemical Pharmacology, vol. 180, p. 114188, 2020.
[28] R. Steiner and K. Hellmann, “Dexrazoxane prevention of anthracycline cardiomyopathy,” *Journal of Clinical Oncology,* vol. 31, p. 1379, 2013.

[29] T. Nousiainen, E. Vanninen, E. Jantunen et al., “Neuroendocrine changes during the evolution of doxorubicin-induced left ventricular dysfunction in adult lymphoma patients,” *Clinical Science,* vol. 101, no. 6, pp. 601–607, 2001.

[30] N. Potocnik, M. Perse, A. Cerar, R. Injac, and Ž. Finderle, “Cardiac autonomic modulation induced by doxorubicin in a rodent model of colorectal cancer and the influence of fullerenol pretreatment,” *PloS One,* vol. 12, no. 7, p. e0181632, 2017.

[31] P. F. Binkley, E. Nunziata, G. J. Haas, S. D. Nelson, and R. J. N. Potocnik, M. Perse, A. Cerar, R. Injac, and, vol. 22, no. 10, pp. 1147–1153, 2013.

[32] Y. Sha, B. J. Scherlag, L. Yu et al., “Low-level right vagal stimulation: anticholinergic and antiadrenergic effects,” *Journal of Cardiovascular Electrophysiology,* vol. 22, no. 10, pp. 1147–1153, 2011.

[33] M. Chen, X. Zhou, L. Yu et al., “Low-level vagus nerve stimulation attenuates myocardial ischemic reperfusion injury by antioxidative stress and antiapoptosis reactions in canines,” *Journal of Cardiovascular Electrophysiology,* vol. 27, no. 2, pp. 224–231, 2016.

[34] S. Wang, H. M. Han, Z. W. Pan et al., “Choline inhibits angiotensin II-induced cardiac hypertrophy by intracellular calcium signal and p38 MAPK pathway,” *Naunyn-Schmiedeberg’s Archives of Pharmacology,* vol. 385, no. 8, pp. 823–831, 2012.

[35] P. Detopoulou, D. B. Panagiotakos, S. Antonopoulou, C. Petsavos, and C. Stefanadis, “Dietary choline and betaine intakes in relation to concentrations of inflammatory markers in healthy adults: the ATTICA study,” *The American Journal of Clinical Nutrition,* vol. 87, no. 2, pp. 424–430, 2008.

[36] Y. Wang, S. S. Po, B. J. Scherlag, L. Yu, and H. Jiang, “The role of low-level vagus nerve stimulation in cardiac therapy,” *Expert Review of Medical Devices,* vol. 16, no. 8, pp. 675–682, 2019.

[37] M. J. Shen, T. Shinohara, H. W. Park et al., “Continuous low-level vagus nerve stimulation reduces stellate ganglion nerve activity and paroxysmal atrial tachyarrhythmias in ambulatory canines,” *Circulation,* vol. 123, no. 20, pp. 2204–2212, 2011.

[38] L. Yu, B. Huang, S. S. Po et al., “Low-level trigus stimulation for the treatment of ischemia and reperfusion injury in patients with ST-segment elevation myocardial infarction: a proof-of-concept study,” *JACC. Cardiovascular Interventions,* vol. 10, no. 15, pp. 1511–1520, 2017.

[39] B. M. Barkat, H. I. Ahmed, H. I. Bahr, and A. M. Elbahaie, “Protective effect of boswellic acids against doxorubicin-induced hepatotoxicity: impact on Nrf2/HO-1 defense pathway,” *Oxidative Medicine and Cellular Longevity,* 2018, Article ID 8296451, 10 pages, 2018.

[40] C. Menale, L. J. Robinson, E. Palagano et al., “Absence of dipeptidyl peptidase 3 increases oxidative stress and causes bone loss,” *Journal of Bone and Mineral Research,* vol. 34, no. 11, pp. 2133–2148, 2019.

[41] S. Rejitha, P. Prathibha, and M. Indira, “Nrf2-mediated antioxidant response by ethanolic extract of Sida cordifolia provides protection against alcohol-induced oxidative stress in liver by upregulation of glutathione metabolism,” *Redox Report,* vol. 20, no. 2, pp. 75–80, 2015.